-
RISS 활용도 분석
-
일본/중국/유럽자료
-
최신/인기 학술자료
-
해외논문구매대행(E-DDS)
http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : 이영열 (검색결과 130 건)
- 무료
- 기관 내 무료
- 유료
-
-
-
-
-
-
이영열 한양대학교 의과대학 2000 한양의대 학술지 Vol.20 No.2
Hematologic malignancies and some solid tumors have been effectively treated by conventional doses of chemotherapy. However, those patients are confronted by relapse due to minimal residual disease. Therefore, more effective treatment stratege is needed for cure or increase of survival. Hematopoietic stem cell transplantation(HSCT) is a kind of organ transplantation and can be used as a curable treatment stratege in some malignant patients. HSCT can be classifed into bone marrow transplantation and peripheral blood stem cell transplantation according to the source of hematopoietic stem cells. If donor of hematopoietic stem cell is the healthy person, we call it allogeneic HSCT, and if donor of hematopoietic stem cell is the patient himself, that is autologous HSCT. In this article, HSCT is briefly introduced for the easy access to clinicians.
-
-
-
-
이영열,임영효,Jae,Hoon,Kim,신진호,Jae,Ung,Lee,김경수,김순길,Jeong,Hyun,Kim,임헌길 대한혈액학회 2010 Blood Research Vol.45 No.2
Essential thrombocythemia (ET) is a chronic myeloproliferative disorder with a prolonged clinical course. Since this disorder is considered to be at increased risk of thromboembolism, therapy is mainly focused on the decreased risk of thrombohemorrhagic events by use of cytotoxic agents. Anagrelide is a phosphodiesterase III inhibitor which is utilized in the treatment of ET for the reduction of platelets. However, patients treated with anagrelide might experience cardiovascular adverse effects including myocardial infarction (MI), although these events are rare. Herein, we report a case of a 30-year-old female with well controlled ET by anagrelide, who eventually developed an acute non-ST elevation myocardial infarction (MI). There has no found any cardiovascular risk factors in this ET patient, strongly suggesting that anagrelide might be the cause of MI. Therefore, cardiovascular function should be monitored in those patients prescribed with anagrelide.
